Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse populations, and what to do when presented with moderate-penetrance mutations.
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognostic markers for this type of breast cancer.
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Miguel Martín, MD, PhD, of the Instituto de Investigacion Sanitaria Gregorio Marañón, discuss phase III study findings on adjuvant capecitabine after standard chemotherapy for people with early triple-negative breast cancer (Abstract GS2-04).
Shoshana M. Rosenberg, ScD, of Dana-Farber Cancer Institute, discusses her study findings on the lower quality of life associated with mastectomy, and the need for intervention and timely referrals to supportive resources, especially for underserved populations (Abstract GS6-04).
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, and Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center debate whether all women with breast cancer and positive lymph nodes should receive chemotherapy.
Hope S. Rugo, MD, of the University of California, San Francisco, summarizes a spotlight session she chaired, which included discussion of new immunotherapy drug combinations, predictive factors, and the immune microenvironment.
